Registration Dossier

Diss Factsheets

Administrative data

Description of key information

200 mg/kg was the No-Observed-Adverse-Effect-Level (NOAEL) for 3-(Dimethylamino)propylurea when administered to rats by oral gavage for 28 days. Minimal effects were seen at a dose of 1000 mg/kg/day. (OECD 407) Bayer 1986

The "No Observed Effect Level (NOEL) was, therefore, considered to be 500 mg/kg/day. (OECD 407) MB Research

Key value for chemical safety assessment

Toxic effect type:
dose-dependent

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records

Referenceopen allclose all

Endpoint:
repeated dose toxicity: oral, other
Type of information:
experimental study
Adequacy of study:
key study
Study period:
2006
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
Version / remarks:
The study was designed to investigate the systemic toxicity of the test material and complies with the following guidelines:
i) Commission Directive 96154tEC (Method B7).
ii) The Japanese Ministry of Health and Welfare (MHW) Guidelines 1986 for a twenty-eight day repeat dose oral toxicity study as required by the Japanese Chemical Substances Control Law 1973 of the Ministry of Economy Trade and Industry (METI) amended 1986.
iii) The OECD Guidelines for Testing of Chemicals No. 407 "Repeated Dose 28 Day Oral Toxicity Study in Rodents" (Adopted 28 July 1995).
iv) USA Environmental Protection Agency (EPA) Health Effects Test Guidelines, OPPTS 870.3050 Repeated Dose 28-Day Toxicity Study in Rodents, July 2000.
GLP compliance:
yes (incl. QA statement)
Specific details on test material used for the study:
Sponsor's identification : 3-DMAPAU
Description : white turbid viscous liquid
Lot number : 18207-61C
Date received : 19 April 2004
Storage conditions : room temperature in the dark under nitrogen
Species:
rat
Strain:
Sprague-Dawley
Sex:
male/female
Details on test animals or test system and environmental conditions:
A sufficient number of male and female Sprague-Dawley Crl:CD (SD ) BR strain rats were obtained from Charles River (UK) Limited, Margate, Kent. On receipt the animals were examined for signs of ill-health or injury. The animals were acclimatised for ten days during which time their health status was assessed. A total of sixty animals (thirty males and thirty females) were accepted into the study. At the start of treatment the males weighed 180 to 25 lg, the females weighed 141 to 195g, and were approximately five to six weeks old.
The animals were housed in groups of five by sex in polypropylene grid-floor cages suspended over trays lined with absorbent paper. The animals were allowed free access to food and water.
A pelleted diet (Rodent 5LF2 (Certified) Diet, International Product Supplies Ltd., Northants, UK) was used. A certificate of analysis of the batch of diet used is given in Appendix 15. Mains drinking water was supplied from polycarbonate bottles attached to the cage. The diet and drinking water were considered not to contain any contaminant at a level that might have affected the purpose or integrity of the study. Environmental enrichment was provided in the form of wooden chew blocks (B & K Universal Ltd., Hull, UK) and cardboard fun tunnels (Datesand Ltd., Cheshire, UK).
The animals were housed in a single air-conditioned room within the Safepharm Barrier Maintained Rodent Facility. The rate of air exchange was at least fifteen air changes per hour and the low intensity fluorescent lighting was controlled to give twelve hours continuous light and twelve hours darkness. Environmental conditions were continuously monitored by a computerised system, and print-outs of hourly mean temperatures and humidities were included in the study records. The temperature and relative humidity controls were set to achieve target values of 21 h 2•‹C and 55 k 15% respectively. Deviations from these targets were considered not to have affected the purpose or integrity of the study.
The animals were randomly allocated to treatment groups using random letter tables and the group mean bodyweights were then determined to ensure similarity between the treatment groups.
The cage distribution within the holding rack was also randornised. The animals were uniquely identified within the study by an ear punching system routinely used in these laboratories.
Route of administration:
oral: gavage
Details on route of administration:
The test material was administered by gavage to three groups, each of five male and five female Sprague-Dawley Cr1:CDB (SD) IGS BR strain rats, for twenty-eight consecutive days, at dose levels of 25,250 and 500 mg/kg/day. A control group of five males and five females was dosed with vehicle alone (distilled water).
Vehicle:
water
Details on oral exposure:
The test material was administered daily, for twenty-eight consecutive days, by gavage using a stainless steel cannula attached to a disposable plastic syringe. Control animals were treated in an identical manner with 5 ml/kg/day of distilled water. Recovery group animals were maintained for a further fourteen days treatment-free period following termination of treatment.
Two recovery groups, each of five males and five females, were treated with the high dose (500 mg/kg/day) or the vehicle alone for twenty-eight consecutive days and then maintained without treatment for a further fourteen days.
The volume of test and control material administered to each animal was based on the most recent bodyweight and was adjusted at weekly intervals
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
The concentration of 3-DMAPAU in the test material formulations was determined by high performance liquid chromatography (HPLC) using an external standard technique. The test material formulations were sampled and analysed within four days of preparation.
Duration of treatment / exposure:
Two recovery groups, each of five males and five females, were treated with the high dose (500 mg/kg/day) or the vehicle alone for twenty-eight consecutive days and then maintained without treatment for a further fourteen days.
Frequency of treatment:
The test material was administered daily, for twenty-eight consecutive days, by gavage using a stainless steel cannula attached to a disposable plastic syringe
Dose / conc.:
25 mg/kg bw/day (nominal)
Remarks:
Oral administration of 3-DMAPAU to rats, by gavage, at dose levels of 25,250 and
i 500 mg/kg/day for twenty-eight consecutive days produced no toxicologically significant changes in any of the treatment groups.
Dose / conc.:
250 mg/kg bw/day (nominal)
Remarks:
Oral administration of 3-DMAPAU to rats, by gavage, at dose levels of 25,250 and
i 500 mg/kg/day for twenty-eight consecutive days produced no toxicologically significant changes in any of the treatment groups.
Dose / conc.:
500 mg/kg bw/day (nominal)
Remarks:
Oral administration of 3-DMAPAU to rats, by gavage, at dose levels of 25,250 and
i 500 mg/kg/day for twenty-eight consecutive days produced no toxicologically significant changes in any of the treatment groups.
No. of animals per sex per dose:
The test material was administered by gavage to three groups, each of five male and five female Sprague-Dawley Cr1:CDB (SD) IGS BR strain rats.
Control animals:
yes, concurrent vehicle
Observations and examinations performed and frequency:
All animals were examined fox overt signs of toxicity, ill-health or behavioural change immediately before dosing and one and five hours after dosing during the working week.
Animals were observed immediately before dosing and one hour after dosing at weekends and public holidays. During the treatment-free period, animals were observed twice daily, morning and afternoon (once daily at weekends). All observations were recorded.
Sacrifice and pathology:
An increase in both kidney and spleen weight was evident in males and females treated with 250 mg/kg/day.
Clinical signs:
no effects observed
Description (incidence and severity):
No toxicologically important clinical sings were detected in any animal throughout the study
Mortality:
no mortality observed
Description (incidence):
There were no unscheduled deaths during the study.
Body weight and weight changes:
no effects observed
Description (incidence and severity):
No adverse effect on bodyweight development was detected.
Food consumption and compound intake (if feeding study):
no effects observed
Description (incidence and severity):
There was no adverse effect on food consumption throughout the study.
Food efficiency:
no effects observed
Description (incidence and severity):
Food efficiency in test animals was similar to that of controls.
Water consumption and compound intake (if drinking water study):
no effects observed
Description (incidence and severity):
Daily visual inspection of water bottles revealed no overt intergroup differences.
Ophthalmological findings:
not specified
Haematological findings:
no effects observed
Description (incidence and severity):
No toxicologically significant effects were detected in the haematological parameters measured.
Clinical biochemistry findings:
no effects observed
Description (incidence and severity):
Blood Chemistry. No toxicologically significant effects were detected in the blood chemical parameters measured.
Urinalysis findings:
no effects observed
Description (incidence and severity):
No treatment-related effects were detected and statistical evaluation of the quantitative data revealed no significant differences.
Behaviour (functional findings):
no effects observed
Description (incidence and severity):
No treatment-related effects were detected.
Immunological findings:
not specified
Organ weight findings including organ / body weight ratios:
no effects observed
Description (incidence and severity):
There were no treatment-related changes in the organ weights measured
Gross pathological findings:
not specified
Neuropathological findings:
no effects observed
Description (incidence and severity):
Necropsy. No treatment-related findings were observed.
Histopathological findings: non-neoplastic:
no effects observed
Description (incidence and severity):
Histopathology. No treatment-related changes were observed.
Histopathological findings: neoplastic:
not specified
Other effects:
not specified
Details on results:
Clinical signs, functional observations, bodyweight development and food and water consumption were monitored during the study. Haematology, blood chemistry and urinalysis were evaluated for all surviving non-recovery group animals at the end of the treatment period and for all recovery group animals at the end of the treatment-free period.
All animals were subjected to gross necropsy examination and histopathological evaluation of selected tissues was performed.
Mortality. There were no unscheduled deaths during this study.
Clinical Observations. No toxicologically important clinical sings were detected in any animal throughout the study.
Functional Observations.
Behavioral Assessment. No treatment-related effects were detected.
Functional Performance Tests. No treatment-related effects were detected.
Sensory Reactivity Assessments. No treatment-related effects were detected.
Bodyweight. No adverse effect on bodyweight development was detected.
Food Consumption. There was no adverse effect on food consumption throughout the study. Food efficiency in test animals was similar to that of controls.
Water Consumption. Daily visual inspection of water bottles revealed no overt intergroup differences.
Haematology. No toxicologically significant effects were detected in the haematological parameters measured.
Blood Chemistry. No toxicologically significant effects were detected in the blood chemical parameters measured.
Urinalysis. No treatment-related effects were detected and statistical evaluation of the quantitative data revealed no significant differences.
Organ Weights. There were no treatment-related changes in the organ weights measured.
Necropsy. No treatment-related findings were observed.
Histopathology. No treatment-related changes were observed.
Key result
Dose descriptor:
NOEL
Effect level:
ca. 500 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
behaviour (functional findings)
body weight and weight gain
clinical biochemistry
clinical signs
food consumption and compound intake
food efficiency
haematology
histopathology: non-neoplastic
mortality
neuropathology
organ weights and organ / body weight ratios
urinalysis
water consumption and compound intake
Key result
Critical effects observed:
no
Conclusions:
Oral administration of 3-DMAPAU to rats, by gavage, at dose levels of 25, 250 and 500 mg/kg/day for twenty-eight consecutive days produced no toxicologically significant changes in any of the treatment groups.
The "No Observed Effect Level (NOEL) was, therefore, considered to be 500 mg/kg/day
Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Study period:
1986
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
guideline study
Qualifier:
according to guideline
Guideline:
OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
GLP compliance:
yes
Species:
rat
Strain:
Wistar
Details on species / strain selection:
Bor:WISW(SPF Cpb), Versuchstierzucht Winkelmann, Borchen
Sex:
male/female
Details on test animals or test system and environmental conditions:
6-7 weeks old
starting weight:
males: 127 g (112 to 137), females 118 g (110 to 129)
During adoption time the rats were kept in groups in conventional fashion in Makrolon cages of Type III, during test individual in cages of Type II, on dust-free wood granulate (manufacturer: Forsbach GmbH, Solingen) at an ambient temperature of 22 +/– 2 degrees Celsius and a 12-hour light/dark cycle (artificial lighting from 6:00 a.m. to 6:00 p.m. MET) and a relative humidity of approximately 50 %. Ten fold airchange per hour. Weekly desinfection.deploying Gevisol or Rapidosept.
Feed: Altromin1324 Pellets, Altromin GmbH, Lage ad libitum
Water: ad libitum
A sufficient number of male and female Sprague-Dawley Crl:CD (SD ) BR strain rats were obtained from Charles River (UK) Limited, Margate, Kent. On receipt the animals were examined for signs of ill-health or injury. The animals were acclimatised for ten days during which time their health status was assessed. A total of sixty animals (thirty males and thirty females) were accepted into the study. At the start of treatment the males weighed 180 to 25 lg, the females weighed 141 to 195g, and were approximately five to six weeks old.
The animals were housed in groups of five by sex in polypropylene grid-floor cages suspended over trays lined with absorbent paper. The animals were allowed free access to food and water.
A pelleted diet (Rodent 5LF2 (Certified) Diet, International Product Supplies Ltd., Northants, UK) was used. . Mains drinking water was supplied from polycarbonate bottles attached to the cage. The diet and drinking water were considered not to contain any contaminant at a level that might have affected the purpose or integrity of the study. Environmental enrichment was provided in the form of wooden chew blocks (B & K Universal Ltd., Hull, UK) and cardboard fun tunnels (Datesand Ltd., Cheshire, UK).
The animals were housed in a single air-conditioned room within the Safepharm Barrier Maintained Rodent Facility. The rate of air exchange was at least fifteen air changes per hour and the low intensity fluorescent lighting was controlled to give twelve hours continuous light and twelve hours darkness. Environmental conditions were continuously monitored by a computerised system, and print-outs of hourly mean temperatures and humidities were included in the study records. The temperature and relative humidity controls were set to achieve target values of 21 +/- 2 °C and 55 +/- 15% respectively. Deviations from these targets were considered not to have affected the purpose or integrity of the study.
The animals were randomly allocated to treatment groups using random letter tables and the group mean bodyweights were then determined to ensure similarity between the treatment groups.
The cage distribution within the holding rack was also randornised. The animals were uniquely identified within the study by an ear punching system routinely used in these laboratories.
Route of administration:
oral: gavage
Vehicle:
water
Details on oral exposure:
The test material was administered daily with an application volume of constantly 10 ml/kg/day,
Analytical verification of doses or concentrations:
yes
Duration of treatment / exposure:
28 days
Frequency of treatment:
once daily
Dose / conc.:
0 mg/kg bw/day (nominal)
Dose / conc.:
40 mg/kg bw/day (nominal)
Dose / conc.:
200 mg/kg bw/day (nominal)
Dose / conc.:
1 000 mg/kg bw/day (nominal)
No. of animals per sex per dose:
5 males and 5 females per dose
0-40-200-1000 mg/kg
Control animals:
yes, concurrent vehicle
Sacrifice and pathology:
No treatment-related microscopic effects were observed. No delayed effects were seen in the satellite groups following a two week recovery.
Clinical signs:
no effects observed
Mortality:
no mortality observed
Body weight and weight changes:
no effects observed
Description (incidence and severity):
In the males of the 1000 mg/kg dosage group a retarded development in the body weight was observed.
Considered as a treatment effect, reduced over time of treatment.
Food consumption and compound intake (if feeding study):
no effects observed
Food efficiency:
no effects observed
Water consumption and compound intake (if drinking water study):
no effects observed
Ophthalmological findings:
no effects observed
Haematological findings:
no effects observed
Clinical biochemistry findings:
no effects observed
Urinalysis findings:
no effects observed
Behaviour (functional findings):
no effects observed
Immunological findings:
no effects observed
Organ weight findings including organ / body weight ratios:
no effects observed
Gross pathological findings:
no effects observed
Neuropathological findings:
no effects observed
Histopathological findings: non-neoplastic:
no effects observed
Histopathological findings: neoplastic:
no effects observed
Key result
Dose descriptor:
NOAEL
Effect level:
200 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
body weight and weight gain
clinical biochemistry
clinical signs
food consumption and compound intake
gross pathology
mortality
organ weights and organ / body weight ratios
water consumption and compound intake
Key result
Critical effects observed:
no
Conclusions:
The test results did not produce any indication of the test substance having any effects. 200 mg/kg was the No-Observed-Adverse-Effect-Level (NOAEL) for 3-(Dimethylamino)propylurea when administered to rats by oral gavage for 28 days. Minimal effects were seen at a dose of 1000 mg/kg/day. (OECD 407)
200 mg/kg was the No-Observed-Adverse-Effect-Level (NOAEL) for 3-(Dimethylamino)propylurea when administered to rats by oral IravaIre for 28 days. Minimal effects were seen at a dose of 1000 mg/kg/day. (OECD 407)
Executive summary:

5 male and 5 female Wistar rats were given HST 2844 in dosages of 0-40-200-1000 mg/kg body weight one time per day over a period of 28 days via a stomach probe.

The animals were observed and weighed on a regular basis and the food intake was determined. At the end of the treatment, hematological and clinical-chemical tests were

performed and the weight of the organs (testicles, liver, kidneys, adrenal glands) was determined. The organs and the tissue were tested pathologically-anatomically, and the

heart, liver, lungs, spleen, kidneys and adrenal glands were tested histo-pathalogically.

In the males of the 1000 mg/kg dosage group a retarded development in the body weight was observed.

Otherwise, the test results did not produce any indication of the test substance having any effects.

200 mg/kg was the No-Observed-Adverse-Effect-Level (NOAEL) for 3-(Dimethylamino)propylurea when administered to rats by oral IravaIre for 28 days. Minimal effects were seen at a dose of 1000 mg/kg/day. (OECD 407)

Endpoint conclusion
Endpoint conclusion:
adverse effect observed
Dose descriptor:
NOAEL
200 mg/kg bw/day
Study duration:
subacute
Species:
rat
Quality of whole database:
Guidline studies, GLP-conform and Klimish 1. Showing same outcome. Although the Bayer study from 1986 is elder, it is chosen as key study. Providing the more conservative value.

Additional information

Justification for classification or non-classification